Ocular Therapeutix (OCUL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from TD Cowen maintained a Buy rating on the stock and has a $14.00 price target.
Tara Bancroft’s rating is based on several promising developments within Ocular Therapeutix’s clinical trials. The company has successfully streamlined its SOL-R trial, reducing the patient size by approximately one-third, which is expected to expedite the timeline for filing. This strategic move does not compromise the trial’s statistical power or dosing flexibility, making it a strong factor in the Buy rating.
Additionally, the SOL-1 trial has shown exceptional retention rates and protocol adherence, with positive expectations for data release in the first quarter of 2026. The FDA’s agreement to evaluate redosing further strengthens the potential for a favorable label, supporting dosing intervals of every 6 or 12 months. These factors collectively contribute to the optimistic outlook and Buy recommendation for Ocular Therapeutix’s stock.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.